The National Center for Advancing Translational Sciences (NCATS) announces the early termination of NOT-TR-21-017 Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs. NCATS will not accept applications for administrative supplements in response to NOT-TR-21-017 effective immediately due to the end of the declared public health emergency as stated in NOT-OD-23-095 “Expiration of the COVID-19 Public Health Emergency”.

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.

NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:

• PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
• PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
• PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
• RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

In addition, NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) U24 recipients from these FOAs:

• RFA-TR-17-006 CTSA Program Data to Health (CD2H) Coordinating Center (U24)
• RFA-TR-16-021 Coordination Center for the CTSA Program (U24)
• RFA-TR-15-002 CTSA Network - Trial Innovation Centers (TICs) (U24)
• RFA-TR-15-004 Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs)(U24)

NCATS expects to issue 1-4 awards for involvement with clinical studies and trials in support of COVID interventions, as well as providing clinical samples and assessing infectious or convalescent status.

Applications in response to this NOSI must be submitted through the following target opportunity or subsequently reissued equivalents. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of this announcement through the expiration date of this notice and designate “NOT-TR-21-017” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form as directed below.

• PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), which is intended to provide additional funds for NIH grantees for work that falls within the scope of their active grant.

When developing applications in response to this NOSI, all instructions in theSF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-20-272) must be followed, with the following additions:

• Applications will be accepted immediately and on a rolling basis through August 16, 2024 by 5:00 PM local time of the applicant organization. This NOSI expires on August 17, 2024. An application submitted in response to this NOSI that is received on August 17, 2024 or later, will be withdrawn. Applications will be considered for funding in FY21 and subsequent fiscal years through FY24 pending: award timelines, availability of funds, and programmatic priority.

NOT-TR-21-017

Expiration Date: New Date June 22, 2023 (0riginal Date: August 17, 2024) per issuance of NOT-TR-23-023